

October 11, 2022

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Growth)

Release of Research Publication of Affinity Maturation in ADLib® from Chiome Bioscience

A research publication is released on examining of affinity maturation step in human ADLib® system, a proprietry antibody generation system in Chiome Bioscience. The research is published at mAbs, an internationally recognized scientific journal.

The human ADLib® system is an efficient human antibody generation technology in the field of antibody based research and drug development. This system can simultaneously achieve antibody production and affinity improvement. The antibody obtained from human ADLib® can be seamlessly affinity-matured to obtain high-affinity human antibodies in a one-stop order. To expand a possible use of affinity maturation in ADLib®, we examined whether the antibody generated by other methods than ADLib® could be effectively affinity matured in this system. The results demonstrated mammalian antibodies deribed from non- ADLib® system such as mouse hybroma method are successfully applied to affinity maturation process in ADLib®.

Based on this research outcome, we expect to expand the value of core competence for human ADLib® system and accelerate our business focusing on antibody's research and development.

➤ Publication

T i t l e : Fast-tracking antibody maturation using a B cell-based display system

Authors : Hitomi Masuda, Atsushi Sawada, Shu-ichi Hashimoto, Kanako Tamai, Ke-Yi Lin,
Naoto Harigai, Kohei Kurosawa, Kunihiro Ohta, Hidetaka Seo and Hiroshi Itou

Journal : mAbs

Volume 14, 2022 -Issue 1

<https://www.tandfonline.com/doi/full/10.1080/19420862.2022.2122275>

<About ADLib® system technology>

The ADLib® system offers a platform library with unique array space that adds seamless affinity maturation function. It is a rapid one stop order drug discovery and research tool that can complete all the steps necessary for antibody drug discovery such as selection, full-length IgG expression, humanization, and affinity maturation on one in vitro platform.

【Inquiries】

Chiome Bioscience Inc. Investor Relations

E-mail : ir@chiome.co.jp